Blockchain Registration Transaction Record

Pentixapharm Builds Global Evidence for Pentixafor PET in Primary Aldosteronism

Pentixapharm reports new EANM 2026 data supporting Pentixafor PET for non-invasive subtyping of primary aldosteronism, reinforcing the Phase 3 PANDA study.

This news matters because primary aldosteronism is a common but underdiagnosed cause of high blood pressure, and identifying patients with one-sided disease currently requires adrenal vein sampling—an invasive and technically demanding catheter procedure. If Pentixafor PET succeeds in the Phase 3 PANDA study, it could offer a non-invasive imaging alternative that helps guide the choice between surgery and lifelong medical therapy, potentially sparing many patients from an uncomfortable and burdensome examination. The independent data from Europe, Asia, and Australia strengthen the biological rationale for CXCR4-targeted imaging and may accelerate clinical adoption. Beyond hypertension, the same CXCR4 platform is being explored in hemato-oncology, including multiple myeloma and acute myeloid leukemia, where combined imaging and targeted bone marrow conditioning could improve stem cell transplantation outcomes. For patients and clinicians, this represents a step toward more precise, less invasive diagnostic pathways.